Market Cap 2.75B
Revenue (ttm) 0.00
Net Income (ttm) -317.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.14
Volume 4,454,100
Avg Vol 3,077,906
Day's Range N/A - N/A
Shares Out 142.83M
Stochastic %K 18%
Beta 1.30
Analysts Strong Sell
Price Target $39.31

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 786 8230
Fax: 781 786 8866
Address:
1560 Trapelo Road, Waltham, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:54 AM
Actionable Trade Alert for $DYN: Market Context: $DYN closed at $19.51, currently showing a neutral RSI at 47.75, indicating no immediate overbought or oversold conditions. The stock is trading below its 30-day moving average (MA30) of $20.46 but above its 50-day moving average (MA50) of $18.88, suggesting potential upward momentum. Directional Bias: The price is within a range defined by a 60-day high of $25.00 and a low of $11.92, indicating room for growth. The ATR of 1.72 suggests moderate volatility, allowing for strategic entry and exit points. Trade Plan: - Suggested Entry: $19.51 - Stop Loss: $18.50 (5.4% below entry) - Take Profit Targets: 1. $21.00 (7.6% ROI) 2. $22.50 (15.2% ROI) 3. $22.85 (17.8% ROI) With the potential to reach the third target, this trade offers a solid risk-reward ratio. Monitor closely for market changes. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
EthGin
EthGin Dec. 11 at 5:42 PM
$DYN specialty power and energy, could see more attention if grid reliability becomes a hotter topic
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 2:44 PM
$DYN Current Stock Price: $20.74 Contracts to trade: $20 DYN Dec 19 2025 Call Entry: $0.99 Exit: $1.96 ROI: 98% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 1:26 PM
Stifel updates rating for Dyne Therapeutics ( $DYN ) to Buy, target set at 36 → 39.
0 · Reply
VixVictor99
VixVictor99 Dec. 10 at 7:20 PM
$DYN biotech momentum, if it respects support this trend confirmation setup stays attractive
0 · Reply
anachartanalyst
anachartanalyst Dec. 10 at 6:09 PM
$DYN https://anachart.com/wp-content/uploads/ana_temp/1765390180_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 3:11 PM
Oppenheimer has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Outperform with a target price of 11 → 40.
0 · Reply
shinwiedepr
shinwiedepr Dec. 10 at 3:08 PM
$DYN Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock at $18.44 per Share
0 · Reply
jeffgosia6
jeffgosia6 Dec. 10 at 2:28 PM
$DYN upgraded today
0 · Reply
Quantumup
Quantumup Dec. 10 at 1:15 PM
Piper Sandler⬆️ $CAPR's PT to $45 from $20 and reiterated at an Overweight rating. $EWTX $PTCT $SRPT $DYN Piper Sandler in its note to investors: Last Wednesday, the Phase III HOPE-3 (N=106) trial met the primary endpoint showing a significant 1.2 point absolute difference from placebo in the Performance of the Upper Limb 2.0 (PUL 2.0, p=0.029). Deramiocel also met the key cardiac endpoint showing an absolute 2.4% improvement in LVEF, representing a 91% slowing of decline vs. placebo. (p=0.041) Capricor will submit HOPE-3 data as a response to the FDA's CRL under the current BLA for deramiocel in DMD cardiomyopathy by YE:25. We anticipate a Type II 6- month review resulting in potential deramiocel approval by mid'26. Capricor is eligible for an $80 million approval milestone from partner Nippon Shinyaku and could receive a valuable Priority Review Voucher (PRV). We reiterate our Overweight rating and are increasing our 12-month price target to $45 from $20 based on positive HOPE-3 data.
1 · Reply
Latest News on DYN
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday

Dec 10, 2025, 6:00 PM EST - 3 days ago

Why Dyne Therapeutics Stock Was a Big Winner on Wednesday


Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dec 10, 2025, 11:36 AM EST - 3 days ago

Dyne Therapeutics: Why The $350M Public Offering Was Critical


Why Dyne Therapeutics Stock Tanked on Tuesday

Dec 9, 2025, 6:22 PM EST - 4 days ago

Why Dyne Therapeutics Stock Tanked on Tuesday


Why Dyne Therapeutics Stock Was Blasting Higher Today

Dec 8, 2025, 2:47 PM EST - 5 days ago

Why Dyne Therapeutics Stock Was Blasting Higher Today


Why Dyne Therapeutics Stock Was Crushing it This Week

Nov 21, 2025, 3:43 PM EST - 22 days ago

Why Dyne Therapeutics Stock Was Crushing it This Week


Dyne Therapeutics to Present at Upcoming Investor Conferences

Nov 3, 2025, 7:30 AM EST - 5 weeks ago

Dyne Therapeutics to Present at Upcoming Investor Conferences


Why Dyne Therapeutics Stock Crushed the Market on Monday

Oct 27, 2025, 6:17 PM EDT - 6 weeks ago

Why Dyne Therapeutics Stock Crushed the Market on Monday


Dyne Reports Wider Loss in Fiscal Q2

Jul 28, 2025, 9:33 PM EDT - 4 months ago

Dyne Reports Wider Loss in Fiscal Q2


Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Jul 16, 2025, 7:00 AM EDT - 5 months ago

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer


Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 7:30 AM EDT - 9 months ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:54 AM
Actionable Trade Alert for $DYN: Market Context: $DYN closed at $19.51, currently showing a neutral RSI at 47.75, indicating no immediate overbought or oversold conditions. The stock is trading below its 30-day moving average (MA30) of $20.46 but above its 50-day moving average (MA50) of $18.88, suggesting potential upward momentum. Directional Bias: The price is within a range defined by a 60-day high of $25.00 and a low of $11.92, indicating room for growth. The ATR of 1.72 suggests moderate volatility, allowing for strategic entry and exit points. Trade Plan: - Suggested Entry: $19.51 - Stop Loss: $18.50 (5.4% below entry) - Take Profit Targets: 1. $21.00 (7.6% ROI) 2. $22.50 (15.2% ROI) 3. $22.85 (17.8% ROI) With the potential to reach the third target, this trade offers a solid risk-reward ratio. Monitor closely for market changes. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
EthGin
EthGin Dec. 11 at 5:42 PM
$DYN specialty power and energy, could see more attention if grid reliability becomes a hotter topic
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 2:44 PM
$DYN Current Stock Price: $20.74 Contracts to trade: $20 DYN Dec 19 2025 Call Entry: $0.99 Exit: $1.96 ROI: 98% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 1:26 PM
Stifel updates rating for Dyne Therapeutics ( $DYN ) to Buy, target set at 36 → 39.
0 · Reply
VixVictor99
VixVictor99 Dec. 10 at 7:20 PM
$DYN biotech momentum, if it respects support this trend confirmation setup stays attractive
0 · Reply
anachartanalyst
anachartanalyst Dec. 10 at 6:09 PM
$DYN https://anachart.com/wp-content/uploads/ana_temp/1765390180_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 3:11 PM
Oppenheimer has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Outperform with a target price of 11 → 40.
0 · Reply
shinwiedepr
shinwiedepr Dec. 10 at 3:08 PM
$DYN Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock at $18.44 per Share
0 · Reply
jeffgosia6
jeffgosia6 Dec. 10 at 2:28 PM
$DYN upgraded today
0 · Reply
Quantumup
Quantumup Dec. 10 at 1:15 PM
Piper Sandler⬆️ $CAPR's PT to $45 from $20 and reiterated at an Overweight rating. $EWTX $PTCT $SRPT $DYN Piper Sandler in its note to investors: Last Wednesday, the Phase III HOPE-3 (N=106) trial met the primary endpoint showing a significant 1.2 point absolute difference from placebo in the Performance of the Upper Limb 2.0 (PUL 2.0, p=0.029). Deramiocel also met the key cardiac endpoint showing an absolute 2.4% improvement in LVEF, representing a 91% slowing of decline vs. placebo. (p=0.041) Capricor will submit HOPE-3 data as a response to the FDA's CRL under the current BLA for deramiocel in DMD cardiomyopathy by YE:25. We anticipate a Type II 6- month review resulting in potential deramiocel approval by mid'26. Capricor is eligible for an $80 million approval milestone from partner Nippon Shinyaku and could receive a valuable Priority Review Voucher (PRV). We reiterate our Overweight rating and are increasing our 12-month price target to $45 from $20 based on positive HOPE-3 data.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:56 AM
Actionable Trade Alert for $DYN: Market Context: $DYN closed at $18.44, currently trading below its 30-day moving average (MA30) of $20.75 and 50-day moving average (MA50) of $18.60. The RSI at 40.29 indicates a potential for upward momentum, as it is approaching the oversold territory. Directional Bias: The price is within a 60-day range of $11.92 to $25.00, suggesting significant upside potential. Given the current RSI and proximity to MA50, a bullish reversal could be imminent. Trade Plan: - Suggested Entry: $18.50 - Stop Loss: $17.00 (approx. 8% below entry) - Take Profit Targets: 1. $20.00 (Target 1: 8% ROI) 2. $22.00 (Target 2: 19% ROI) 3. $21.50 (Target 3: 16% ROI) With these targets, a strategic approach can yield an overall ROI exceeding 17% on the highest target. Monitor closely for any changes in market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
jdlman
jdlman Dec. 10 at 2:47 AM
$DYN news
0 · Reply
jeffgosia6
jeffgosia6 Dec. 9 at 6:24 PM
0 · Reply
jeffgosia6
jeffgosia6 Dec. 9 at 6:17 PM
$DYN in
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 5:21 PM
Morgan Stanley has updated their rating for Dyne Therapeutics ( $DYN ) to Overweight with a price target of 50.
1 · Reply
notreload_ai
notreload_ai Dec. 9 at 4:26 PM
$DYN plans to raise $300M by selling new shares, with an option for underwriters to buy $45M more. The funds will support its work on treatments for neuromuscular diseases. https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-proposed-public-offering-common-2
0 · Reply
CDCcsd
CDCcsd Dec. 9 at 4:10 PM
$DYN The secondary is about 12% dilutive, not a big deal, and doesn't significantly change any price targets..
1 · Reply
medguy
medguy Dec. 9 at 4:03 PM
Looking for bounce $SLM $DYN $PHR $CMP
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 1:22 PM
Chardan Capital updates rating for Dyne Therapeutics ( $DYN ) to Buy, target set at 38.
1 · Reply
free2dream
free2dream Dec. 9 at 12:47 PM
$SRPT even $DYN has $3.1B market cap on no revenues, Sarepta has $400M just last quarter with all the shit what has happened ! Sarepta ain't 20 dollar stock, what the fuck is wiring with this market
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:45 AM
Actionable Trade Alert for $DYN: Market Context: $DYN closed at $22.11, showing bullish momentum with an RSI of 59.49, indicating potential upward movement but nearing overbought territory. The 30-day moving average (MA30) at $20.94 and 50-day moving average (MA50) at $18.47 suggest a strong upward trend as the price is above both MAs. Directional Bias: The price is currently between the 60-day high of $25.00 and low of $11.92, providing a favorable risk-reward setup. The ATR of 1.53 indicates moderate volatility, allowing for reasonable movement to hit targets. Trade Plan: - Suggested Entry: $22.11 - Stop Loss: $20.50 (3% below entry) - Take Profit Targets: 1. $23.50 (6.3% ROI) 2. $24.50 (6.3% ROI) 3. $25.00 (12.3% ROI) With the potential for a 17% ROI on the third target, this trade offers a solid opportunity. Monitor RSI for signs of overbought conditions as targets approach. https://privateprofiteers.com
0 · Reply
blocktrade
blocktrade Dec. 8 at 10:49 PM
$GPCR $KYMR $DYN all price tomorrow night
0 · Reply